Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kyntra Bio (KYNB) reported third-quarter 2026 revenue of $1.762 million and discontinued its oncology programs following insufficient interim efficacy.
Revenue rose from $1.076 million a year earlier. Continuing operations generated $157,000 in income, or $0.04 per share, versus a $13.146 million loss; results included a $14.011 million debt-restructuring gain. The royalty financing restructuring reduced maximum aggregate payments from $125 million to $65 million, leaving $15 million payable after a $42.6 million accelerated payment.
Kyntra plans a Phase 3 roxadustat trial for anemia in lower-risk myelodysplastic syndromes with high transfusion burden in Q1 2027, conditional on a partnership or external capital raise. It discontinued FG-3246 and FG-3180 and expects over $20 million in operating expense savings in 2027 and 2028. Cash, investments and receivables totaled $44.1 million at September 30; Kyntra expects funding into 2028.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointRoyalty financing restructuring reduced maximum aggregate payments by $60 million, from $125 million to $65 million. 4.3× market cap
- Major point. Forward-looking: it has not happened yet and may not happen.Program termination is expected to save over $20 million in operating expenses in 2027 and 2028.
- Major pointThird-quarter results included a $14.011 million gain on debt restructuring.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Kyntra expects existing cash, investments and receivables to fund operating plans into 2028.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Kyntra plans pivotal roxadustat Phase 3 initiation in Q1 2027 for anemia in lower-risk myelodysplastic syndromes.
- Moderate pointThird-quarter revenue increased to $1.762 million from $1.076 million a year earlier.
- Moderate pointThird-quarter continuing operations earned $157,000, or $0.04 per share, versus a $13.146 million loss, or $3.25 per share.
- Moderate pointNine-month continuing-operations loss narrowed to $3.001 million from $43.594 million a year earlier.
- Moderate pointNine-month results included a $30.940 million gain on deconsolidation of a subsidiary.
2 minor points
- Minor pointThird-quarter interest expense declined to $1.632 million from $2.083 million a year earlier.
- Minor pointTotal liabilities declined to $56.041 million at September 30, 2026, from $115.119 million at December 31, 2025.
Negative
- Major pointFG-3246 and FG-3180 development discontinued after insufficient efficacy at FG-3246’s pre-specified Phase 2 prostate-cancer interim analysis.
- Major pointRoyalty restructuring required a $42.6 million accelerated payment to NQ Project Phoebus. 3.1× market cap
- Moderate pointRoxadustat Phase 3 initiation depends on a strategic partnership or external capital raise.
- Moderate pointThird-quarter net income fell to $157,000 from $200.636 million; prior-year discontinued operations contributed $213.782 million.
- Moderate pointThird-quarter operating loss widened to $12.865 million from $5.411 million a year earlier.
- Moderate pointNine-month revenue declined to $4.026 million from $5.163 million a year earlier.
- Moderate pointNine-month operating loss widened to $44.258 million from $32.383 million a year earlier.
- Moderate pointNine-month net loss was $3.067 million, versus $197.672 million net income a year earlier.
- Moderate pointCash and equivalents declined to $9.905 million from $47.872 million at December 31, 2025.
6 minor points
- Minor pointRemaining royalty payments are capped at $15 million, funded from 50% of specified Astellas drug-product revenue.
- Minor pointThird-quarter research and development expense rose to $8.266 million from $1.209 million a year earlier.
- Minor pointThird-quarter selling, general and administrative expense rose to $5.757 million from $5.295 million a year earlier.
- Minor pointThird-quarter cost of goods sold was $619,000, versus negative $58,000 a year earlier.
- Minor pointShort-term investments declined to $30.385 million from $41.106 million at December 31, 2025.
- Minor pointTotal deficit widened to $28.670 million from $17.005 million at December 31, 2025.
News Explained
The remaining
Key Figures
- Maximum royalty payments
- $125 million to $65 million
- Amended royalty financing agreement
- Remaining royalty payment cap
- $15 million
- Paid from 50% of qualifying Astellas-territory roxadustat revenue
- Accelerated royalty payment
- $42.6 million
- Payment to NQ Project Phoebus under the amended agreement
- Operating expense savings
- Over $20 million
- Expected in 2027 and 2028 from ending the FG-3246 study
- Total revenue
- $1.8 million vs. $1.1 million
- Third quarter 2026 vs. third quarter 2025
- Net income from continuing operations
- $0.2 million vs. net loss of $13.1 million
- Third quarter 2026 vs. third quarter 2025
- Cash, investments, and accounts receivable
- $44.1 million
- As of September 30, 2026; operating plans expected to be funded into 2028
- Planned Phase 3 initiation
- 1Q 2027
- Roxadustat trial; subject to a strategic partnership or external capital raise
Previous Earnings Reports
-
FG-3246 Phase 2 continued enrolling; roxadustat Phase 3 protocol finalized, targeting a 4Q 2026 start.
-
FG-3246 Phase 2 continued; roxadustat Phase 3 initiation targeted for 2H 2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
mcrpc medical
lr-mds medical
hif-ph inhibitors medical
erythropoiesis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Completed restructuring of royalty financing agreement, reducing the maximum aggregate payment obligation by
$60 million , with only$15 million in future royalty-backed payments remaining - Initiation of the pivotal Phase 3 trial of roxadustat for the treatment of anemia in LR-MDS patients with high transfusion burden (HTB) planned in 1Q 2027, subject to the execution of either a strategic partnership or an external capital raise
- Decision to discontinue development of FG-3246 and FG-3180 following insufficient efficacy at the pre-specified Phase 2 interim analysis in metastatic castration-resistant prostate cancer (mCRPC), resulting in a reduction of over
$20 million in operating expenses in 2027 and 2028 - Cash, cash equivalents, investments, and accounts receivable of
$44.1 million as of September 30, 2026, with a cash runway now into 2028 - Kyntra Bio to host conference call and webcast presentation today at 5:00 PM ET
SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the third quarter 2026 and provided an update on the company’s recent developments.
“Following a pre-planned interim analysis showing insufficient efficacy, we have made the decision to terminate the FG-3246 Phase 2 trial,” said Thane Wettig, Chief Executive Officer of Kyntra Bio. “We continue to work towards the completion of our transformation to a pure-play, rare disease company laser-focused on the initiation and execution of the Phase 3 roxadustat trial. The unmet medical need and corresponding multi-billion-dollar commercial opportunity in LR-MDS is significant. Subject to the execution of either a strategic partnership or an external capital raise, we plan on initiating the pivotal Phase 3 trial in the first quarter of 2027.”
Key Highlights of Third Quarter, Recent Developments, and Upcoming Milestones
Roxadustat
- Initiation of the pivotal Phase 3 trial of roxadustat for the treatment of anemia in patients with LR-MDS and HTB planned in the first quarter of 2027, subject to the execution of either a strategic partnership or an external capital raise.
FG-3246 (CD46 Targeting ADC) and FG-3180 (CD46 Targeting PET Imaging Agent)
- Following a pre-specified interim analysis of the ongoing Phase 2 study of FG-3246 in mCRPC, the Company decided to close enrollment in the study and discontinue development of the program.
- Preliminary efficacy results at the interim analysis did not meet the threshold required to support continued development.
- The Company plans to complete the close-out of the study over the coming months and will cancel all planned future investment in the program.
- The Company expects to save over
$20 million in operating expenses in 2027 and 2028 from the termination of the study.
Corporate
- In August 2026, the company signed an amendment and restatement of its existing royalty financing agreement with NQ Project Phoebus, L.P., materially reducing its payment obligations under the agreement in exchange for an accelerated upfront payment. The amendment included the following terms:
- Reduction of the maximum aggregate payments under the agreement from
$125 million to$65 million , including the$42.6 million accelerated payment to NQ Project Phoebus, L.P., bringing total payments made to date to$50 million , a full return of NQ Project Phoebus, L.P.’s invested capital. - Remaining payments, capped at
$15 million , to be paid from50% of the roxadustat drug product revenue Kyntra Bio recognizes from Astellas in the Astellas territories excluding Japan. - Once the
$15 million cap is reached, the amended agreement will terminate, with Kyntra Bio retaining all subsequent EVRENZO™ royalties in the Astellas territories.
- Reduction of the maximum aggregate payments under the agreement from
- Appointed Andrew E. Singer, MBA to the Board of Directors.
Financial
- Total revenue from continuing operations for the third quarter of 2026 was
$1.8 million , as compared to$1.1 million for the third quarter of 2025. - Net income from continuing operations for the third quarter of 2026 was
$0.2 million , or$0.04 net income per basic and diluted share, compared to a net loss of$13.1 million , or$3.25 net loss per basic and diluted share, one year ago. - As of September 30, 2026, Kyntra Bio reported
$44.1 million in cash, cash equivalents, investments, and accounts receivable. - The Company expects its cash, cash equivalents, investments, and accounts receivable to be sufficient to fund operating plans into 2028.
Conference Call and Webcast Presentation
Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on Kyntra Bio’s website.
About Roxadustat
Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin.
Roxadustat is approved in Europe, Japan, China, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD). Kyntra Bio has the sole rights to roxadustat in the United States, Canada, Mexico, and in all markets not held by AstraZeneca or licensed to Astellas. Astellas and Kyntra Bio are collaborating on the commercialization of roxadustat for the treatment of anemia in territories including Japan, Europe, Turkey, Russia, and the Commonwealth of Independent States, the Middle East, and South Africa.
Following promising results from the Phase 2/3 MATTERHORN study, the Company is planning to study roxadustat in a pivotal Phase 3 trial in patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB).
About Kyntra Bio
Kyntra Bio is a pure play, rare disease biopharmaceutical company focused on the development of roxadustat for anemia associated with lower-risk myelodysplastic syndromes (LR-MDS). Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company is planning to study roxadustat in a pivotal Phase 3 trial in patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS). For more information, please visit www.kyntrabio.com.
Forward-Looking Statements
This release contains forward-looking statements regarding Kyntra Bio’s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its partners Fortis and UCSF. These forward-looking statements include, but are not limited to, statements regarding the efficacy, safety, and potential clinical or commercial success of Kyntra Bio products and product candidates, statements under the caption “Recent Highlights and Upcoming Milestones”, statements about regulatory interactions, statements regarding cash, such as the expectation that cash, cash equivalents and accounts receivable will be sufficient to fund Kyntra Bio’s operating plans into 2028, and statements about Kyntra Bio’s plans and objectives. These forward-looking statements are typically identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. Kyntra Bio’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in Kyntra Bio’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Kyntra Bio undertakes no obligation to update any forward-looking statement in this press release, except as required by law.
Condensed Consolidated Balance Sheets
(In thousands)
| September 30, 2026 | December 31, 2025 | ||||||
| (Unaudited) | (1) | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 9,905 | $ | 47,872 | |||
| Short-term investments | 30,385 | 41,106 | |||||
| Accounts receivable, net | 3,848 | 216 | |||||
| Inventory | 3,255 | 3,743 | |||||
| Prepaid expenses and other current assets | 1,227 | 6,136 | |||||
| Total current assets | 48,620 | 99,073 | |||||
| Long-term investments | — | 20,160 | |||||
| Other assets | 231 | 361 | |||||
| Total assets | $ | 48,851 | $ | 119,594 | |||
| Liabilities, stockholders’ equity and non-controlling interests | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 4,581 | $ | 3,745 | |||
| Accrued and other liabilities | 31,005 | 20,183 | |||||
| Deferred revenue | 6,170 | 5,314 | |||||
| Total current liabilities | 41,756 | 29,242 | |||||
| Product development obligations | — | 19,560 | |||||
| Deferred revenue, net of current | 2,957 | 255 | |||||
| Liability related to sale of future revenues, non-current | 11,268 | 65,980 | |||||
| Other long-term liabilities | 60 | 82 | |||||
| Total liabilities | 56,041 | 115,119 | |||||
| Redeemable non-controlling interests | 21,480 | 21,480 | |||||
| Total stockholders’ deficit attributable to Kyntra Bio | (29,190 | ) | (30,038 | ) | |||
| Nonredeemable non-controlling interests | 520 | 13,033 | |||||
| Total deficit | (28,670 | ) | (17,005 | ) | |||
| Total liabilities, redeemable non-controlling interests and deficit | $ | 48,851 | $ | 119,594 | |||
(1) The condensed consolidated balance sheet amounts at December 31, 2025 are derived from audited financial statements.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| (Unaudited) | |||||||||||||||
| Revenue: | |||||||||||||||
| Development and other revenue | $ | 99 | $ | 119 | 449 | 396 | |||||||||
| Drug product revenue, net | 1,663 | 957 | 3,577 | 4,767 | |||||||||||
| Total revenue | 1,762 | 1,076 | 4,026 | 5,163 | |||||||||||
| Operating costs and expenses: | |||||||||||||||
| Cost of goods sold | 619 | (58 | ) | 4,727 | 278 | ||||||||||
| Research and development | 8,266 | 1,209 | 22,654 | 16,249 | |||||||||||
| Selling, general and administrative | 5,757 | 5,295 | 20,951 | 20,459 | |||||||||||
| Restructuring charge | (15 | ) | 41 | (48 | ) | 560 | |||||||||
| Total operating costs and expenses | 14,627 | 6,487 | 48,284 | 37,546 | |||||||||||
| Loss from operations | (12,865 | ) | (5,411 | ) | (44,258 | ) | (32,383 | ) | |||||||
| Interest and other, net: | |||||||||||||||
| Interest expense | (1,632 | ) | (2,083 | ) | (6,426 | ) | (6,346 | ) | |||||||
| Gain on deconsolidation of subsidiary | — | — | 30,940 | — | |||||||||||
| Loss on debt extinguishments | — | (6,583 | ) | — | (6,583 | ) | |||||||||
| Gain on debt restructuring | 14,011 | — | 14,011 | — | |||||||||||
| Interest income and other income (expenses), net | 643 | 931 | 2,731 | 1,628 | |||||||||||
| Total interest and other, net | 13,022 | (7,735 | ) | 41,256 | (11,301 | ) | |||||||||
| Income (loss) from continuing operations before income taxes | 157 | (13,146 | ) | (3,002 | ) | (43,684 | ) | ||||||||
| Benefit from income taxes | — | — | (1 | ) | (90 | ) | |||||||||
| Income (loss) from continuing operations | 157 | (13,146 | ) | (3,001 | ) | (43,594 | ) | ||||||||
| Income (loss) from discontinued operations, net of tax | — | 213,782 | (66 | ) | 241,266 | ||||||||||
| Net income (loss) | $ | 157 | $ | 200,636 | $ | (3,067 | ) | $ | 197,672 | ||||||
| Income (loss) from continuing operations per share - basic and diluted | $ | 0.04 | $ | (3.25 | ) | $ | (0.74 | ) | $ | (10.79 | ) | ||||
| Income (loss) from discontinued operations per share - basic and diluted | — | 52.86 | (0.02 | ) | 59.69 | ||||||||||
| Net income (loss) per share - basic and diluted | $ | 0.04 | $ | 49.61 | $ | (0.76 | ) | $ | 48.90 | ||||||
| Weighted average number of common shares used to calculate net income (loss) per share: | |||||||||||||||
| Basic | 4,049 | 4,044 | 4,048 | 4,042 | |||||||||||
| Diluted | 4,050 | 4,044 | 4,048 | 4,042 | |||||||||||
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@kyntrabio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did Kyntra Bio discontinue FG-3246 and FG-3180?
Kyntra discontinued the programs after preliminary FG-3246 efficacy results failed to meet the threshold for continued development at the pre-specified Phase 2 interim analysis in metastatic castration-resistant prostate cancer. Enrollment is closing, study close-out is planned over the coming months, and all planned future investment in the program will be canceled.
When does Kyntra Bio plan to start the roxadustat Phase 3 trial?
Kyntra plans to initiate the pivotal trial in the first quarter of 2027, subject to executing either a strategic partnership or an external capital raise. The trial would study anemia in patients with lower-risk myelodysplastic syndromes and high transfusion burden.
How will Kyntra Bio pay its remaining royalty financing obligation?
The remaining payments, capped at $15 million, will come from 50% of roxadustat drug-product revenue Kyntra recognizes from Astellas in Astellas territories excluding Japan. Once that cap is reached, the amended agreement terminates and Kyntra retains all subsequent EVRENZO royalties in the Astellas territories.